Newron Pharmaceuticals is a Swiss biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for the central nervous system. Founded in the mid-1990s and headquartered in Balerna, Switzerland, Newron has built a pipeline of small-molecule candidates targeting neurological and psychiatric disorders with high unmet medical need. The company’s expertise spans medicinal chemistry, preclinical pharmacology and early- to late-stage clinical development.
The company’s flagship product, Xadago® (safinamide), is approved for adjunctive treatment of Parkinson’s disease and is marketed through strategic partnerships in Europe and select international territories. Beyond safinamide, Newron’s pipeline includes sarizotan for treatment of respiratory and motor symptoms in Rett syndrome, nelotanserin for behavioral disturbances in dementia-related conditions, and additional early-stage programs in pain and neurodegeneration. These programs are supported by Newron’s proprietary platform for central nervous system-targeted small molecules, which emphasizes selectivity, safety and oral bioavailability.
Newron serves patients and healthcare providers across Europe, North America and Asia through licensing and co-development agreements with leading pharmaceutical companies. The company maintains research facilities in Switzerland and collaborates with academic institutions and contract research organizations to advance its clinical programs. Regulatory interactions to date include orphan drug designations and fast-track reviews in key markets, reflecting the company’s focus on rare neurological disorders.
Under the leadership of Chief Executive Officer Paolo Paoletti and an experienced board of directors, Newron continues to expand its scientific and commercial capabilities. The management team combines expertise in neuroscience drug discovery, clinical development, regulatory affairs and global commercialization. With a mission to bring novel treatments to patients with neurological diseases, Newron remains committed to advancing its existing portfolio while exploring new therapeutic opportunities in the central nervous system space.
AI Generated. May Contain Errors.
